Antibody-drug conjugates (ADCs) are a rapidly emerging class of cancer therapeutics that combine the targeting power of antibodies with the potent killing power of chemotherapy drugs. This targeted approach to cancer treatment has the potential to revolutionize the way cancer is treated, with over 100 ADCs in clinical trials and more than 15 approved by regulatory agencies worldwide. For leaders of R&D, this idea in brief highlights key players, forces, and publication trends that enable better navigation of the opportunities ahead.
Download the Executive Summary
